Telix to Acquire Germany’s ITM for $1.65 Billion Upfront in Radiopharmaceutical Consolidation

What happened

Telix Pharmaceuticals, an Australian maker of radioactive diagnostics, agreed to acquire all of the stock of German radiopharmaceutical developer ITM Isotope Technologies Munich. The deal was announced on Sunday, Sept. 20, U.S. time, and reported widely on Monday, Sept. 21. According to BioPharma Dive, the transaction carries an upfront value of $1.65 billion, and Telix could pay up to another $700 million if ITM’s lead therapy, ITM-11, meets certain approval and sales targets.

Telix shareholders will own about 76.3% of the combined company, with ITM shareholders holding the rest.

Deal details

• Upfront value: $1.65 billion. Dakota’s September transaction summary breaks that down as about $1.25 billion in shares, $302 million of assumed net debt and $96 million of rollover and expenses.
• Contingent payments: Up to $700 million tied to ITM-11 approval and sales milestones.
• Approvals: Telix’s board has approved the deal, as have holders of more than 90% of ITM’s shares.
• Timing: Expected to close by the end of Telix’s 2026 fiscal year.

Company details

ITM, founded about 22 years ago, supplies raw materials for radiopharmaceuticals and has more than 10 programs in development. Its isotope manufacturing and distribution network spans more than 65 countries, and its supply business generated $273 million in 2025 sales, according to BioPharma Dive.

ITM-11 pairs lutetium-177 with a compound targeting the SSTR protein, the same approach used by Novartis’s Lutathera, and has been tested in the neuroendocrine tumor type Lutathera is approved to treat. U.S. regulators rejected ITM-11 in August; ITM said the decision reflected manufacturing concerns and issues at a third-party commercial facility rather than clinical data. Telix says a Phase 3 study in a second indication could read out in 2027.

Telix sells several cancer diagnostics and has therapeutics in development. The combined company is expected to bring in more than $1.3 billion in revenue and income this year, BioPharma Dive reported.

William Blair analyst Andy Hsieh wrote, “We believe the transaction will allow Telix to further corner the industry.”

Why it matters for the sector

Radiopharmaceuticals, which use radioactive isotopes attached to targeting molecules to image or treat tumors, have become one of the most active areas of oncology dealmaking. A key constraint on the field is supply: medical isotopes must be produced, purified and shipped on tight timelines, and manufacturing problems can delay approvals, as ITM-11’s rejection shows.

By combining Telix’s diagnostics with ITM’s isotope production and distribution, the deal creates a more vertically integrated company with greater control over the value chain. Telix says ITM-11 could also accelerate its entry into therapeutics and expand its presence in neuroendocrine tumors.

The deal structure, which relies largely on Telix shares, contingent payments and assumed debt, reflects the risk around ITM-11’s regulatory path. Paying part of the value only if the therapy is approved and reaches sales targets shifts some of that risk to ITM’s shareholders.

The transaction also illustrates how mid-sized companies are consolidating to compete with large pharma, which has acquired several radiopharmaceutical developers in recent years.

What to watch

• ITM’s plans to address the manufacturing issues cited in the FDA rejection and the timing of a resubmission.
• Closing of the deal by the end of Telix’s fiscal year.
• The Phase 3 readout for ITM-11 in a second indication, expected as early as 2027.
• Further consolidation among isotope suppliers and radiopharmaceutical developers.

Sources: BioPharma Dive, Dakota

How Radiopharmaceuticals Work

A radiopharmaceutical combines two elements: a targeting molecule that seeks out a feature of cancer cells, and a radioactive isotope that either reveals where those cells are or damages them. The choice of isotope determines the purpose.

• Diagnostic isotopes emit radiation that imaging scanners, such as PET or SPECT, can detect, showing where the targeting molecule has gathered in the body.
• Therapeutic isotopes emit radiation, such as beta or alpha particles, that travels a short distance and damages the DNA of nearby cells.

When a diagnostic and a therapeutic version share the same target, doctors can first image a patient to confirm the tumor expresses the target and then treat with the therapeutic version. This pairing is often called theranostics, and it is one reason companies with strong diagnostics businesses see value in adding therapeutics.

Lutetium-177 and SSTR

Lutetium-177 is a beta-emitting isotope with a half-life of roughly a week, long enough to be shipped but short enough to require tight logistics. SSTR refers to somatostatin receptors, which many neuroendocrine tumors display at high levels, making them a well-established target for this kind of therapy.

Why Supply Chains Decide Winners in This Field

Radioactive drugs decay on a fixed schedule, so they cannot be stockpiled like conventional medicines. Production involves several tightly linked steps:

1. Isotope production, typically in nuclear reactors or particle accelerators.
2. Purification and processing to pharmaceutical standards.
3. Radiolabeling, in which the isotope is attached to the targeting molecule.
4. Quality release and shipping, often within narrow time windows, to treatment centers.
5. Administration at sites licensed to handle radioactive materials.

A failure at any step can delay patient treatment, and regulators scrutinize each facility involved. That is why manufacturing control features so prominently in the strategic case for combining isotope supply with drug development.

Questions Readers Ask

What is a complete response letter?

When the FDA declines to approve an application in its current form, it issues a complete response letter explaining the deficiencies. A company can address them and resubmit.

Why pay largely in shares?

Using stock conserves cash and gives the seller’s shareholders a continuing stake in the combined company’s performance.

What is assumed net debt?

Debt of the acquired company, minus its cash, that the buyer takes on as part of the purchase. It counts toward the deal’s total value.

Are these therapies widely available?

Availability depends on approvals in each country and on treatment centers equipped to handle radioactive drugs. Patients should consult their own oncologists.

What does vertical integration mean here?

It means one company controls more stages of the process, from producing isotopes to developing, imaging with and selling the finished drugs. Owning those links can reduce dependence on outside suppliers, though it also means carrying the cost and regulatory responsibility of running complex facilities.

What are neuroendocrine tumors?

Cancers that arise from cells with both nerve-like and hormone-producing features, most often in the digestive tract, pancreas or lungs. Many grow slowly, and many display somatostatin receptors.

This article is for general information only and is not investment advice.